Heart failure in patients with preserved and deteriorated left ventricular ejection fraction

Heart

Volumn 91, Issue 4, 2005, Pages 489-494

  Varela Roman, A ^a   Grigorian, L ^a   Barge, E ^a   Bassante, P ^a   De La Pena M G ^a   Gonzalez Juanatey, J R ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGE; AGED; ARTICLE; CONGESTIVE CARDIOMYOPATHY; DRUG USE; FEMALE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SEX RATIO; SURVIVAL; VALVULAR HEART DISEASE; ADOLESCENT; CONGESTIVE HEART FAILURE; EPIDEMIOLOGY; HEART STROKE VOLUME; HOSPITALIZATION; MIDDLE AGED; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; EPIDEMIOLOGIC METHODS; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 15844399394     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2003.031922     Document Type: Article

References (34)

1. Hovranek EP, Masoudi FA, Westfall KA, et al. Spectrum of heart failure in older patients: results from the national heart failure project. Am Heart J 2002;143:12-7.
2. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population. The Rotterdam study. Eur Heart J 1999;20:447-55.
3. Gonzalez-Juanatey JR, Alegria E, Lozano JV, et al, Impacto de la hipertensión en las cardiopatías en España. Estudio CARDIOTENS 1999. Rev Esp Cardiol 2001;54:139-49.
4. García-Acuña JM, González-Juanatey JR, Alegría E, et al. La fibrilación auricular permanente en las enfermedades cardiovasculares en España. Estudio CARDIOTENS 1999. Rev Esp Cardiol 2002;55:943-52.
5. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function, epidemiology, clinical characteristics and prognosis. J Am Coll Cardiol 2004;43:317-27.
6. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007-18.
7. Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202.
8. Ahmed A, Roseman JM, Duxbury AS, et al. Correlates and outcomes of preserved left ventricular systolic function among older adults hospitalized with heart failure. Am Heart J 2002;144:365-72.
9. Senni M, Redfield MM. Heart failure with preserved systolic function: a different natural history. J Am Coll Cardiol 2001;38:1277-82.
10. Yusuf S, Pfeffer MA, Swedberg K, for the CHARM Investigators and Committees, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial, Lancet 2003;362:777-81.
11. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction. J Am Coll Cardiol 1999;33:1948-55.
12. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmstea County, Minnesota, in 1991. Circulation 1998;98:2282-9.
13. Varela-Román A, Gonzalez-Juanatey JR, Basante P, et al. Clinical characteristics and prognosis of hospitalised inpatients with heart failure and preserved or reduced left ventricular ejection fraction. Heart 2002;88:249-54.
14. Cowie MR, Fox KF, Wood DA, et al. Hospitalisation of patients with heart failure: a population-based study. Eur Heart J 2002;23:877-85.
15. La insuficiencia cardíaca en los servicios de medicina interna (estudio SEMI-IC). Grupo de Trabajo de Insuficiencia Cardíaca de la Sociedad Española de Medicina Interna (SEMI). Med Clin (Barc) 2002;118:605-10.
16. Zile MR, Brutsaert DI. New concepts in diastolic dysfunction and diastolic heart failure. II. Casual mechanisms and treatment. Circulation 2002;105:1503-8.
17. Zile MR, Gaasch WH, Carroll JD, et al. Heart failure with normal election fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 2001;104:779-85.
18. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000;101:2118-21.
19. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. Valsartan heart failure trial investigators. N Engl J Med 2001;345:1667-75.
20. CIBIS II Investigators. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. Lancet 1999;353:9-13.
21. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-7.
22. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
23. Blackledge HM, Tomlinson J, Squire IB. Prognosis far patients newly admitted to hospital with heart failure: survival trends in 12220 index admissions in Leicestershire 1993-2001. Heart 2003;89:615-20.
24. Bouvy ML, Heerdink ER, Leufkens HGM, et al. Predicting mortality in patients with heart failure: a pragmatic approach. Heart 2003;89:605-9.
25. Gustafsson F, Torp-Pedersen C, Brendorp B, et al, for the DIAMOND study group. Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function. Eur Heart J 2003;24:863-70.
26. Hellermann JP, Jacobsen SJ, Reeder GS, et al. Heart failure after myocardial infarction: prevalence of preserved left ventricular systolic function in the community. Am Heart J 2003;145:742-8.
27. Kitzman DW. Heart failure with normal systolic function. Clin Geriatr Med 2000;16:489-512.
28. Weinberg EO, Thienelt CD, Katz SE, et al. Gender differences in molecular remodelling in pressure overload hypertrophy. J Am Coll Cardiol 1999;34:264-73.
29. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995;26:1565-74.
30. Setaro JF, Soufer R, Remetz MS, et al. Long-term outcome in patients with congestive heart failure and intact left ventricular systolic performance. Am J Cardiol 1992;69:1212-6.
31. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
32. American College of Cardiology, American Heart Association. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2001;38:2101-13.
33. Task Force Report. Guidelines for the diagnosis and treatment of chronic heart failure. European Society of Cardiology. Eur Heart J 2001;22:1527-60.
34. McMurray J, Ostergren J, Pfeffer M, on behalf of the CHARM Committees and Investigators, et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM) programme. Eur J Heart Fail 2003;5:261-70.